Jon O Ebbert1, Herbert H Severson2, Brian G Danaher2, Neal L Benowitz3, Darrell R Schroeder4. 1. Primary Care Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN; ebbert.jon@mayo.edu. 2. Department of Psychology, Oregon Research Institute, Eugene, OR; 3. Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, CA. 4. Primary Care Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN;
Abstract
INTRODUCTION: The nicotine metabolite ratio (NMR) of 3'-hydroxycotinine to cotinine is a noninvasive marker of the rate of nicotine metabolism. Fast metabolism (ie, a high NMR) is associated with lower cigarette smoking abstinence rates using transdermal nicotine replacement. We evaluated whether the NMR can be used to predict self-reported nicotine lozenge use and tobacco abstinence among smokeless tobacco users treated for tobacco dependence. METHODS: This was a secondary analysis of data from one arm of a large trial. Participants received quitting support materials and 4-mgnicotine lozenges by mail plus three coaching phone calls. Saliva kits were mailed for collection of saliva samples, which were analyzed for cotinine and 3'-hydroxycotinine. Self-reported tobacco and lozenge use were assessed at 3 months. Analyses were performed using Spearman rank correlation and logistic regression. RESULTS: Of the 160 saliva collection kits mailed, 152 were returned. The NMR was not significantly correlated with the baseline amount of smokeless tobacco used, the number of years of tobacco use, or the level of tobacco dependence as measured by the Severson Smokeless Tobacco Dependency Scale. The NMR was positively correlated with lozenge use (r = 0.21, P = .015), but it did not predict self-reported 7-day point prevalence abstinence at 3 months. CONCLUSIONS: Fast metabolizers may need to self-administer more nicotine replacement in the form of nicotine lozenges to achieve the same clinical response achieved by slower metabolizers using fewer lozenges.
RCT Entities:
INTRODUCTION: The nicotine metabolite ratio (NMR) of 3'-hydroxycotinine to cotinine is a noninvasive marker of the rate of nicotine metabolism. Fast metabolism (ie, a high NMR) is associated with lower cigarette smoking abstinence rates using transdermal nicotine replacement. We evaluated whether the NMR can be used to predict self-reported nicotine lozenge use and tobacco abstinence among smokeless tobacco users treated for tobacco dependence. METHODS: This was a secondary analysis of data from one arm of a large trial. Participants received quitting support materials and 4-mg nicotine lozenges by mail plus three coaching phone calls. Saliva kits were mailed for collection of saliva samples, which were analyzed for cotinine and 3'-hydroxycotinine. Self-reported tobacco and lozenge use were assessed at 3 months. Analyses were performed using Spearman rank correlation and logistic regression. RESULTS: Of the 160 saliva collection kits mailed, 152 were returned. The NMR was not significantly correlated with the baseline amount of smokeless tobacco used, the number of years of tobacco use, or the level of tobacco dependence as measured by the Severson Smokeless Tobacco Dependency Scale. The NMR was positively correlated with lozenge use (r = 0.21, P = .015), but it did not predict self-reported 7-day point prevalence abstinence at 3 months. CONCLUSIONS: Fast metabolizers may need to self-administer more nicotine replacement in the form of nicotine lozenges to achieve the same clinical response achieved by slower metabolizers using fewer lozenges.
Authors: M Nakajima; J T Kwon; N Tanaka; T Zenta; Y Yamamoto; H Yamamoto; H Yamazaki; T Yamamoto; Y Kuroiwa; T Yokoi Journal: Clin Pharmacol Ther Date: 2001-01 Impact factor: 6.875
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Matthew J Binnington; Andy Z X Zhu; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2012-06 Impact factor: 2.089
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman Journal: Pharmacol Biochem Behav Date: 2008-10-31 Impact factor: 3.533
Authors: Brian V Fix; Richard J O'Connor; Neal Benowitz; Bryan W Heckman; K Michael Cummings; Geoffrey T Fong; James F Thrasher Journal: Nicotine Tob Res Date: 2017-09-01 Impact factor: 4.244
Authors: Joshua L Karelitz; Erin A McClure; Caitlin Wolford-Clevenger; Lauren R Pacek; Karen L Cropsey Journal: Drug Alcohol Depend Date: 2021-02-03 Impact factor: 4.492
Authors: Patricia Di Ciano; Rachel F Tyndale; Esmaeil Mansouri; Christian S Hendershot; Alan A Wilson; Dina Lagzdins; Sylvain Houle; Isabelle Boileau; Bernard Le Foll Journal: Int J Neuropsychopharmacol Date: 2018-06-01 Impact factor: 5.176